Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells

Nature Medicine

Volumn 6, Issue 9, 2000, Pages 1011-1017

  Nair, Smita K ^a   Heiser, Axel ^a   Boczkowski, David ^a   Majumdar, Anish ^b   Naoe, Michio ^a   Lebkowski, Jane S ^b   Vieweg, Johannes ^a   Gilboa, Eli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b GERON CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ENZYME; RNA; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL LINE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; KIDNEY CARCINOMA; LYMPHOCYTE ACTIVATION; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; THYMOMA; TUMOR IMMUNITY;

ANIMAL; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CELL TRANSFORMATION, VIRAL; DENDRITIC CELLS; H-2 ANTIGENS; HERPESVIRUS 4, HUMAN; HUMAN; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROSTATIC NEOPLASMS; RNA; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; TELOMERASE; VACCINES, SYNTHETIC;

EID: 0033826798     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/79519     Document Type: Article

References (42)

1. Rosenberg, S.A. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10, 281-287 (1999).
2. Boon, T. & van der Bruggen, P. Human tumor antigens recognized by T lymphocytes, J. Exp. Med. 183, 725-729 (1996).
3. Blackburn, E.H. Structure and function of telomeres. Nature 350, 569-573 (1991).
4. Greider, C.W. Telomere length regulation. Annu. Rev. Biochem. 65, 337-365 (1996).
5. Nodes, R.J. Telomere length, aging, and somatic cell turnover. J. Exp. Med. 190, 153-156 (1999).
6. Weng, N.P., Hathcock, K.S & Modes, R.J. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity 9, 151-157 (1998).
7. Hiyama, K. et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 155, 3711-3715 (1995).
8. Prowse, K.R. & Greider, C.W. Developmental and tissue-specific regulation of mouse telomerase and telomere length. Proc. Natl. Acad. Sci. USA 92, 4818-4822 (1995).
9. Shay, J.W. & Bacchetti, S. A survey of telomerase activity in human cancer, Eur. J. Cancer 33, 787-791 (1997).
10. Kim, N.W. et al. Specific association of human telomerase activity with immortal cells and cancer [see comments]. Science 266, 2011-2015 (1994).
11. Greenberg, R.A., Allsopp, R.C., Chin, L., Morin, G.B. & DePinho, R.A. Expression of mouse telomerase reverse transcriptase during development, differentiation and proliferation. Oncogene 16, 1723-1730 (1998).
12. Ramakrishnan, S., Eppenberger, U., Mueller, H., Shinkai, Y. & Narayanan, R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res. 58, 622-625 (1998).
13. Meyerson, M. et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-795 (1997).
14. Kilian, A. et al. Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Hum. Mol. Genet. 6, 2011-2019 (1997).
15. Vonderheide, R.H., Hahn, W.C., Schultze, J.L. & Nadler, L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10, 673-679 (1999).
16. Yewdell, J.W., Norbury, C.C. & Bennink, J.R. Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73, 1-77 (1999).
17. Simpson, E., Gordon, R. D. Responsiveness to H-Y antigen: Ir gene complementation and target cell specificity. Immunol. Rev. 35, 59-75 (1977).
18. Ashley, D.M. et al. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186, 1177-1182 (1997).
19. Boczkowski, D., Nair, S.K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
20. Nair, S.K. et al. Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. Int. J. Cancer 82, 121-124 (1999).
21. Nair, S.K. et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nature Biotechnol. 16, 364-369 (1998).
22. Boczkowski, D., Nair, S.K., Nam, J.H., Lyerly, H.K. & Gilboa, E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res. 60, 1028-1034 (2000).
23. Piatyszek, M.A. et al. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol (TRAP). Methods Cell Sci. 17, 1-15 (1995).
24. Yewdell, J.W. & Bennink, J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 17, 51-88 (1999).
25. Porgador, A., Feldman, M. & Eisenbach, L. H-2Kb transfection of 816 melanoma cells results in reduced tumourigenicity and metastatic competence. J. Immunogenet. 16, 291-303 (1989).
26. Coveney, E., Clary, B., Iacobucci, M., Philip, R. & Lyerly, K. Active immunotherapy with transiently transfected cytokine-secreting tumor cells inhibits breast cancer metastases in tumor-bearing animals. Surgery 120, 265-272; discussion 272-263 (1996).
27. Hicklin, D.J., Marincola, F.M. & Ferrone, S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol. Med. Today 5, 178-186 (1999).
28. Garrido, F. et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours, Immunol. Today 18, 89-95 (1997)
29. Weidt, G., Utermohlen, O., Heukeshoven, J., Lehmann-Grube, F. & Deppert, W. Relationship among immunodominance of single CD8+ T cell epitopes, virus load, and kinetics of primary antiviral CTL response. J. Immunol. 160, 2923-2931 (1998).
30. Mylin, L.M., Bonneau, R.H., Lippolis, J.D. & Tevethia, S.S. Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J. Virol. 69, 6665-6677 (1995).
31. Fu, T.M., Friedman, A., Ulmer, J.B., Liu, M.A. & Donnelly, J.J. Protective cellular immunity: cytotoxic T-lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. 71, 2715-2721 (1997).
32. Chen, Y., Webster, R.G. & Woodland, D.L. Induction of CD8+ T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J. Immunol. 160, 2425-2432 (1998).
33. Oukka, M. et al. Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 157, 3039-3045 (1996).
34. Van Waes, C., Monach, P.A., Urban, J.L., Wortzel, R.D. & Schreiber, H. Immunodominance deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro. Tissue Antigens 47, 399-407 (1996).
35. Johnston, J.V. et al B7-CD28 costimulation unveils the hierarchy of tumor epitopes recognized by major histocompatibility complex class I-restricted CD8+ cytolytic T lymphocytes. J. Exp. Med. 183, 791-800 (1996).
36. Gilboa, E. The makings of a tumor rejection antigen [In Process Citation]. Immunity 11, 263-270 (1999).
37. Srivastava, P.K. Do human cancers express shared protective antigens? or the necessity of remembrance of things past. Semin. Immunol. 8, 295-302 (1996).
38. Moore, M.W., Carbone, F.R. & Bevan, M.J. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 54, 777-785 (1988).
39. DeKernion, J.B., Soloway, M.S. & Persky, L. Chemotherapy of experimental transitional-cell carcinoma. Urology 4, 63-68 (1974).
40. Inaba, K. et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176, 1693-1702 (1992).
41. Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
42. Volgmann, T., Klein-Struckmeier, A. & Mohr, H. A fluorescence-based assay for quantitation of lymphokine-activated killer cell activity. J. Immunol Methods 119, 45-51 (1989).